Suppr超能文献

患者和陪伴者共同参与决策,对痴呆诊断时开始使用胆碱酯酶抑制剂药物的决策感到满意。

Patient and companion shared decision making and satisfaction with decisions about starting cholinesterase medication at dementia diagnosis.

机构信息

School of Health Sciences, City University of London.

College of Medicine and Health, University of Exeter.

出版信息

Age Ageing. 2019 Sep 1;48(5):711-718. doi: 10.1093/ageing/afz045.

Abstract

BACKGROUND

there is little research on how people with dementia are involved in treatment decisions at diagnosis.

OBJECTIVE

to measure shared decision making when starting cholinesterase inhibitors, investigate associations with contextual factors and explore satisfaction and experience of the diagnostic meeting.

SETTING

nine UK memory clinics in two geographical locations.

SUBJECTS

74 people receiving dementia diagnoses (with 69 companions) and 21 doctors.

METHODS

we video-recorded 74 memory clinic consultations and rated doctor-shared decision making behaviours using the Observing Patient Involvement in Decision Making scale (OPTION-5 scale). Patients and companions rated their satisfaction and experience. Mixed-effects regressions investigated involvement and (i) number people present, meeting length, capacity, cognitive functioning, diagnosis; and (ii) patient/companion satisfaction and consultation experience.

RESULTS

mean consultation time was 26.7 min. Mean OPTION-5 score was 22.5/100 (Standard Deviation = 17.3). Doctors involved patients in decisions more often when patients had mixed dementia (β = 10.13, 95% confidence interval 1.25-19.0, P = 0.025) and in shorter meetings (β = -0.51, 95% CI -0.87 to -0.15, P = 0.006). Patient and companion satisfaction were high and not associated with whether doctors invited patient involvement. Half of patients and one-third companions were uncertain about the meeting outcome, experienced communication barriers and negative emotions.

CONCLUSIONS

consultations scored low on shared decision making, but were comparable to other settings and were not lower with more cognitively impaired patients. Negative patient and companion experiences reflect the importance of supporting healthcare providers to address patient and companion emotions and need for information.

摘要

背景

关于痴呆症患者在诊断时如何参与治疗决策的研究甚少。

目的

衡量开始使用胆碱酯酶抑制剂时的共同决策情况,调查其与背景因素的关联,并探讨对诊断会议的满意度和体验。

设置

两个地理位置的 9 家英国记忆诊所。

受试者

74 名接受痴呆诊断的患者(有 69 名同伴)和 21 名医生。

方法

我们对 74 次记忆诊所咨询进行了录像,并使用参与决策观察量表(OPTION-5 量表)对医生的共同决策行为进行了评分。患者和同伴对其满意度和体验进行了评分。混合效应回归分析了参与度以及:(i)在场人数、会议时长、能力、认知功能、诊断;以及(ii)患者/同伴满意度和咨询体验。

结果

平均咨询时间为 26.7 分钟。平均 OPTION-5 得分为 22.5/100(标准差为 17.3)。当患者患有混合性痴呆症时(β = 10.13,95%置信区间为 1.25-19.0,P = 0.025),以及在较短的会议中(β = -0.51,95%CI-0.87 至-0.15,P = 0.006),医生更常让患者参与决策。患者和同伴的满意度都很高,与医生是否邀请患者参与决策无关。一半的患者和三分之一的同伴对会议结果不确定,经历了沟通障碍和负面情绪。

结论

咨询在共同决策方面得分较低,但与其他环境相当,且对于认知能力受损更严重的患者,得分并没有更低。患者和同伴的负面体验反映了支持医疗保健提供者解决患者和同伴的情绪以及对信息的需求的重要性。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验